Showing results (451-460 of 475) with videos related to

Sort By:
Pageof 48
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 27, 2019
An Extensively Humanized Mouse Model to Predict Pathways of Drug Disposition and Drug/Drug Interactions, and to Facilitate Design of Clinical TrialsC J Henderson, Y Kapelyukh, N Scheer, et al.
European Journal of Gastroenterology & Hepatology|May 8, 2001
Transjugular intra-hepatic portosystemic shunt for refractory variceal bleedingT Bizollon, J Dumortier, C Jouisse, et al.
Gastroenterologie Clinique Et Biologique|April 15, 2008
[Pseudoaneurysm of the hepatic artery: rare complication of chronic pancreatitis]A-M Marion-Audibert, A Mesnil, M Guillet, et al.
Microbiome|March 21, 2019
Mining, analyzing, and integrating viral signals from metagenomic dataTingting Zheng, Jun Li, Yueqiong Ni, et al.
Journal of Virology|July 20, 2001
Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patientsD J Kempf, J D Isaacson, M S King, et al.
AIDS Research and Human Retroviruses|December 28, 2007
A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeksJean-Michel Molina, Thomas J Podsadecki, Margaret A Johnson, et al.
Journal De Radiologie|September 12, 2002
[Imaging of osteoarticular tuberculosis]L Boussel, B Marchand, N Blineau, et al.
Nutrition & Metabolism|October 16, 2009
Differential changes in serum uric acid concentrations in sibutramine promoted weight loss in diabetes: results from four weeks of the lead-in period of the SCOUT trialCharlotte Andersson, Peter Weeke, Bente Brendorp, et al.
AIDS (London, England)|April 16, 1998
The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadirD J Kempf, R A Rode, Y Xu, et al.
BMC Endocrine Disorders|February 27, 2010
The weight lowering effect of sibutramine and its impact on serum lipids in cardiovascular high risk patients with and without type 2 diabetes mellitus - an analysis from the SCOUT lead-in periodPeter Weeke, Charlotte Andersson, Emil L Fosbøl, et al.
Pageof 48